DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1

raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

An extensive clinical trial programme


ADULTS AND ADOLESCENTS:
DUPIXENT was studied in one Phase 2b and two Phase 3 clinical trials including 2,888 patients aged 12 years and older, for up to 52 weeks1

INTRODUCING THE DUPIXENT PRE-FILLED PEN


DUPIXENT can be administered via
a pre-filled pen or a syringe1


 


Adult and adolescent trial design

Learn more about how the clinical trials have been designed.


Find out more


Safety profile

Learn more about the safety profile of DUPIXENT.

 


Find out more


Dosing

Learn more about how DUPIXENT can be administered.



Find out more

    References

    1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, June 2022.

MAT-GB-2004975(v7.0) | Date of preparation: June 2022